Neumora Discontinues Navacaprant Development for Depression
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Development Failure: Neumora Therapeutics announced that its navacaprant drug did not achieve statistical significance in the Phase 3 KOASTAL-2 and -3 studies for treating major depressive disorder, leading to the decision to discontinue its development, which directly impacts the company's future product pipeline and market competitiveness.
- Workforce Reduction: The company plans to reduce its workforce by approximately 35%, a move that not only reflects the financial pressure from the failed development but may also affect internal morale and future innovation capabilities, further weakening its position in the biopharmaceutical industry.
- Stock Price Decline: Following the announcement of the development failure, Neumora's stock price experienced a significant drop, undermining investor confidence and potentially leading more shareholders to seek legal recourse for losses, increasing the legal risks faced by the company.
- Legal Investigation: Holzer & Holzer, LLC is investigating whether Neumora violated federal securities laws, encouraging investors who suffered losses to contact legal counsel to protect their rights, highlighting potential compliance issues within the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NMRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NMRA
Wall Street analysts forecast NMRA stock price to rise
8 Analyst Rating
5 Buy
2 Hold
1 Sell
Moderate Buy
Current: 1.780
Low
3.00
Averages
9.33
High
18.00
Current: 1.780
Low
3.00
Averages
9.33
High
18.00
About NMRA
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Neumora Therapeutics Shares Plunge 50% After Phase 3 Trial Failure
- Trial Failure: Neumora Therapeutics' shares plummeted approximately 50% on Monday after the phase 3 trial for navacaprant in major depressive disorder missed its primary endpoint, leading to the abandonment of the asset's development, which significantly impacts the company's future product pipeline and market competitiveness.
- Workforce Reduction: The company announced a 35% workforce cut, expected to yield annual cost savings of around $10 million, although this comes with one-time restructuring costs of approximately $2 million, a move aimed at optimizing operational efficiency in response to the financial pressures from the trial failure.
- Cash Flow Status: Neumora stated it has sufficient cash to operate through Q3 2027, indicating a degree of financial stability to maintain basic operations despite facing significant challenges following the trial results.
- Other R&D Projects: The company continues to advance NMRA-511 for Alzheimer's disease agitation, NMRA-898 for schizophrenia, and NMRA-215 for cardiometabolic diseases, demonstrating ongoing efforts in diversifying its product pipeline, although the setback with navacaprant poses strategic challenges.
See More
Neumora Therapeutics Cuts 35% Workforce to Conserve Cash
- Drug Development Setback: Neumora Therapeutics' lead drug navacaprant failed to outperform placebo in two late-stage trials, causing shares to plummet nearly 47%, indicating a significant setback in the company's efforts in the depression treatment market and shaking investor confidence.
- Workforce Reduction: To conserve cash and refocus resources, the company plans to cut approximately 35% of its workforce, generating around $10 million in annual savings, a strategic move aimed at sustaining operations until the third quarter of 2027.
- Pipeline Outlook: Despite the disappointing results from navacaprant, Neumora remains optimistic about its remaining pipeline, including NMRA-511 for Alzheimer's agitation, NMRA-898 for schizophrenia, and NMRA-215 for cardiometabolic conditions, with multiple clinical data readouts expected over the next 12 months.
- Market Sentiment: Despite the stock's sharp decline, retail sentiment on Stocktwits remains in the 'extremely bullish' territory, with seven out of nine analysts rating the stock as 'Buy' or higher, and a 12-month price target of $8.91 suggesting a potential upside of over 400%.
See More
Neumora Discontinues Navacaprant Development for Depression
- Development Failure: Neumora Therapeutics announced that its navacaprant drug did not achieve statistical significance in the Phase 3 KOASTAL-2 and -3 studies for treating major depressive disorder, leading to the decision to discontinue its development, which directly impacts the company's future product pipeline and market competitiveness.
- Workforce Reduction: The company plans to reduce its workforce by approximately 35%, a move that not only reflects the financial pressure from the failed development but may also affect internal morale and future innovation capabilities, further weakening its position in the biopharmaceutical industry.
- Stock Price Decline: Following the announcement of the development failure, Neumora's stock price experienced a significant drop, undermining investor confidence and potentially leading more shareholders to seek legal recourse for losses, increasing the legal risks faced by the company.
- Legal Investigation: Holzer & Holzer, LLC is investigating whether Neumora violated federal securities laws, encouraging investors who suffered losses to contact legal counsel to protect their rights, highlighting potential compliance issues within the company.
See More
Neumora Therapeutics to Participate in Healthcare Conference
- Conference Participation: Neumora Therapeutics will participate in the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, showcasing its latest advancements in biopharmaceuticals, which is expected to attract attention from investors and industry experts, thereby enhancing the company's visibility in the capital markets.
- Live Webcast: The event will feature a live webcast available on the company's website, allowing global investors to stay updated on Neumora's developments in real-time, enhancing transparency and facilitating interaction with potential investors, which could positively impact future fundraising activities.
- Therapeutic Pipeline Overview: Neumora's pipeline focuses on addressing underserved diseases, demonstrating its innovative approach in neuroscience drug development aimed at improving treatment outcomes and quality of life for patients, further solidifying its competitive position in the biopharmaceutical industry.
- Company Mission: Neumora's mission is to redefine neuroscience drug development by introducing next-generation therapies to tackle contemporary medical challenges, emphasizing its strategic importance in driving medical innovation and improving patient lives.
See More
Schall Law Firm Investigates Neumora Securities Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Neumora Therapeutics, Inc. to determine if the company issued false or misleading statements that could affect investor rights.
- Legal Compliance Issues: The investigation focuses on whether Neumora failed to disclose information pertinent to investors, potentially leading to shareholder losses and impacting the company's reputation and future financing capabilities.
- Investor Rights Protection: Schall encourages affected shareholders to participate in the investigation and offers free legal consultations, aiming to help investors understand their rights and seek compensation.
- Securities Litigation Expertise: The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors worldwide, which underscores its professional capability and influence in protecting investor rights.
See More
Neumora Therapeutics Reports Positive Phase Ib Results for Alzheimer's Treatment
- Strong Financial Position: As of December 31, 2025, Neumora Therapeutics reported $182.5 million in cash and equivalents, expected to support operations into Q3 2027, demonstrating the company's financial resilience for ongoing R&D and market expansion.
- Clinical Trial Progress: The Phase Ib study of NMRA-511 showed clinically meaningful effects in Alzheimer's disease agitation with a favorable safety profile, potentially offering new hope for treatment options and enhancing the company's competitive edge in neuroscience.
- New Drug Development Updates: Neumora has fully enrolled participants for the KOASTAL-2 and KOASTAL-3 studies, with data expected in Q2 2026, which will provide critical support for the filing of navacaprant in major depressive disorder, further advancing its therapeutic applications.
- Challenges and Risks: Despite NMRA-215 showing leading weight loss data in a 12-week obesity study, unexpected adverse findings in a 13-week toxicology study have delayed clinical trials until Q1 2027, highlighting the challenges and uncertainties faced in drug development.
See More
Neumora Therapeutics Shares Plunge 50% After Phase 3 Trial Failure
- Trial Failure: Neumora Therapeutics' shares plummeted approximately 50% on Monday after the phase 3 trial for navacaprant in major depressive disorder missed its primary endpoint, leading to the abandonment of the asset's development, which significantly impacts the company's future product pipeline and market competitiveness.
- Workforce Reduction: The company announced a 35% workforce cut, expected to yield annual cost savings of around $10 million, although this comes with one-time restructuring costs of approximately $2 million, a move aimed at optimizing operational efficiency in response to the financial pressures from the trial failure.
- Cash Flow Status: Neumora stated it has sufficient cash to operate through Q3 2027, indicating a degree of financial stability to maintain basic operations despite facing significant challenges following the trial results.
- Other R&D Projects: The company continues to advance NMRA-511 for Alzheimer's disease agitation, NMRA-898 for schizophrenia, and NMRA-215 for cardiometabolic diseases, demonstrating ongoing efforts in diversifying its product pipeline, although the setback with navacaprant poses strategic challenges.
See More
Neumora Therapeutics Cuts 35% Workforce to Conserve Cash
- Drug Development Setback: Neumora Therapeutics' lead drug navacaprant failed to outperform placebo in two late-stage trials, causing shares to plummet nearly 47%, indicating a significant setback in the company's efforts in the depression treatment market and shaking investor confidence.
- Workforce Reduction: To conserve cash and refocus resources, the company plans to cut approximately 35% of its workforce, generating around $10 million in annual savings, a strategic move aimed at sustaining operations until the third quarter of 2027.
- Pipeline Outlook: Despite the disappointing results from navacaprant, Neumora remains optimistic about its remaining pipeline, including NMRA-511 for Alzheimer's agitation, NMRA-898 for schizophrenia, and NMRA-215 for cardiometabolic conditions, with multiple clinical data readouts expected over the next 12 months.
- Market Sentiment: Despite the stock's sharp decline, retail sentiment on Stocktwits remains in the 'extremely bullish' territory, with seven out of nine analysts rating the stock as 'Buy' or higher, and a 12-month price target of $8.91 suggesting a potential upside of over 400%.
See More
Neumora Discontinues Navacaprant Development for Depression
- Development Failure: Neumora Therapeutics announced that its navacaprant drug did not achieve statistical significance in the Phase 3 KOASTAL-2 and -3 studies for treating major depressive disorder, leading to the decision to discontinue its development, which directly impacts the company's future product pipeline and market competitiveness.
- Workforce Reduction: The company plans to reduce its workforce by approximately 35%, a move that not only reflects the financial pressure from the failed development but may also affect internal morale and future innovation capabilities, further weakening its position in the biopharmaceutical industry.
- Stock Price Decline: Following the announcement of the development failure, Neumora's stock price experienced a significant drop, undermining investor confidence and potentially leading more shareholders to seek legal recourse for losses, increasing the legal risks faced by the company.
- Legal Investigation: Holzer & Holzer, LLC is investigating whether Neumora violated federal securities laws, encouraging investors who suffered losses to contact legal counsel to protect their rights, highlighting potential compliance issues within the company.
See More
Neumora Therapeutics to Participate in Healthcare Conference
- Conference Participation: Neumora Therapeutics will participate in the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, showcasing its latest advancements in biopharmaceuticals, which is expected to attract attention from investors and industry experts, thereby enhancing the company's visibility in the capital markets.
- Live Webcast: The event will feature a live webcast available on the company's website, allowing global investors to stay updated on Neumora's developments in real-time, enhancing transparency and facilitating interaction with potential investors, which could positively impact future fundraising activities.
- Therapeutic Pipeline Overview: Neumora's pipeline focuses on addressing underserved diseases, demonstrating its innovative approach in neuroscience drug development aimed at improving treatment outcomes and quality of life for patients, further solidifying its competitive position in the biopharmaceutical industry.
- Company Mission: Neumora's mission is to redefine neuroscience drug development by introducing next-generation therapies to tackle contemporary medical challenges, emphasizing its strategic importance in driving medical innovation and improving patient lives.
See More
Schall Law Firm Investigates Neumora Securities Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Neumora Therapeutics, Inc. to determine if the company issued false or misleading statements that could affect investor rights.
- Legal Compliance Issues: The investigation focuses on whether Neumora failed to disclose information pertinent to investors, potentially leading to shareholder losses and impacting the company's reputation and future financing capabilities.
- Investor Rights Protection: Schall encourages affected shareholders to participate in the investigation and offers free legal consultations, aiming to help investors understand their rights and seek compensation.
- Securities Litigation Expertise: The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors worldwide, which underscores its professional capability and influence in protecting investor rights.
See More
Neumora Therapeutics Reports Positive Phase Ib Results for Alzheimer's Treatment
- Strong Financial Position: As of December 31, 2025, Neumora Therapeutics reported $182.5 million in cash and equivalents, expected to support operations into Q3 2027, demonstrating the company's financial resilience for ongoing R&D and market expansion.
- Clinical Trial Progress: The Phase Ib study of NMRA-511 showed clinically meaningful effects in Alzheimer's disease agitation with a favorable safety profile, potentially offering new hope for treatment options and enhancing the company's competitive edge in neuroscience.
- New Drug Development Updates: Neumora has fully enrolled participants for the KOASTAL-2 and KOASTAL-3 studies, with data expected in Q2 2026, which will provide critical support for the filing of navacaprant in major depressive disorder, further advancing its therapeutic applications.
- Challenges and Risks: Despite NMRA-215 showing leading weight loss data in a 12-week obesity study, unexpected adverse findings in a 13-week toxicology study have delayed clinical trials until Q1 2027, highlighting the challenges and uncertainties faced in drug development.
See More
